Gretex Corporate Services Limited (BOM:543324)

CTI BioPharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	18.15	366.41	214.17	35.75	7.22
Depreciation & Amortization, Total	26.41	15.96	4.6	1.68	1.54
Gain (Loss) On Sale of Investments	-29.2	-39.22	-14.01	-1.83	-1.49
Change in Accounts Receivable	-1.22	-15.86	-0.88	7.49	-10.75
Change in Accounts Payable	3.25	-0.62	1.08	-2.32	2.95
Change in Other Net Operating Assets	-49.86	-48.39	25.86	-4.34	-1.08
Other Operating Activities	-142.19	89.66	-118.94	-17.94	3.09
Operating Cash Flow	-310.48	-186.17	105.04	18.48	5.44
Capital Expenditures	-35.59	-210.82	-10.06	-2.62	-0.46
Cash Acquisitions	-	-54.36	-	-	-
Investment in Securities	46.2	-73.44	-65.8	-73.67	-11.54
Other Investing Activities	4.29	6.25	0.08	32.9	1.7
Investing Cash Flow	16.51	-372.15	-75.78	-43.38	-10.3
Short-Term Debt Issued	51.54	-	-	-	-
Long-Term Debt Issued	12.34	42.15	-	-	-
Total Debt Issued	63.88	42.15	-	-	-
Short-Term Debt Repaid	-	-	-1.37	-1.06	-8.93
Long-Term Debt Repaid	-	-	-18.31	-4.3	-2.43
Total Debt Repaid	-	-	-19.68	-5.35	-11.35
Net Debt Issued (Repaid)	63.88	42.15	-19.68	-5.35	-11.35
Issuance of Common Stock	151.6	268.68	-	37.1	20.09
Common Dividends Paid	-7.03	-8.57	-	-	-
Other Financing Activities	70.21	371.29	-2.3	-2.42	-2.91
Financing Cash Flow	278.66	673.54	-21.97	29.32	5.83
Net Cash Flow	-15.3	115.22	7.29	4.42	0.97
Free Cash Flow	-346.06	-397	94.98	15.86	4.98
Free Cash Flow Growth	-	-	498.74%	218.26%	-
Free Cash Flow Margin	-13.16%	-34.08%	62.69%	36.08%	17.54%
Free Cash Flow Per Share	-10.87	-13.81	4.88	0.82	0.35
Cash Interest Paid	5.57	1.76	2.3	2.42	2.91
Cash Income Tax Paid	158.8	-2.67	0.28	0.24	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.